Vaxart (OTCMKTS:VXRT) Releases Earnings Results, Beats Expectations By $0.06 EPS

Vaxart (OTCMKTS:VXRT) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06, Zacks reports. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. The firm had revenue of $27.18 million during the quarter, compared to analyst estimates of $26.21 million.

Vaxart Stock Performance

Shares of Vaxart stock traded down $0.02 during trading hours on Friday, hitting $0.55. The company’s stock had a trading volume of 54,954 shares, compared to its average volume of 553,489. Vaxart has a twelve month low of $0.30 and a twelve month high of $0.84. The firm has a fifty day moving average of $0.56 and a 200-day moving average of $0.63. The stock has a market cap of $132.76 million, a price-to-earnings ratio of 3.64 and a beta of 1.10.

Hedge Funds Weigh In On Vaxart

Hedge funds have recently made changes to their positions in the stock. Invesco Ltd. raised its position in Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after purchasing an additional 70,568 shares during the period. Jones Financial Companies Lllp raised its holdings in shares of Vaxart by 276,364.7% in the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares during the period. Goldman Sachs Group Inc. acquired a new position in Vaxart during the 1st quarter worth about $31,000. Creative Planning purchased a new position in Vaxart during the 2nd quarter valued at about $33,000. Finally, Marshall Wace LLP acquired a new position in Vaxart in the 2nd quarter valued at about $794,000. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.